Suchergebnisse - "Rejeski, Kai"

PubPharm (11)

1

Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma

enthalten in: Blood cancer discovery | 2024

von Faramand, R. | Lee, S. | Jain, M. | +30

2

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Iacoboni, G. | Navarro, V. | Martín-López, A. | +21

3

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

enthalten in: Science advances | 2023

von Rejeski, K. | Perez, A. | Iacoboni, G. | +23

4

Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy

enthalten in: Cancer immunology research | 2023

von Rejeski, K. | Cordas Dos Santos, D. | Parker, N. | +14

CommentIn: Cancer Immunol Res. 2023 Jun 2;11(6):704. - PMID 37264818

5

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL

enthalten in: Blood | 2022

von Rejeski, K. | Wu, Z. | Blumenberg, V. | +11

6

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

enthalten in: Blood | 2022

von Philipp, N. | Kazerani, M. | Nicholls, A. | +22

CommentIn: Blood. 2022 Sep 8;140(10):1056-1058. - PMID 36074532

7

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies

enthalten in: Haematologica | 2022

von Dos Santos, D. | Rejeski, K. | Winkelmann, M. | +10

8

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

enthalten in: Blood advances | 2022

von Rejeski, K. | Burchert, A. | Iacoboni, G. | +14

9

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

enthalten in: Journal for immunotherapy of cancer | 2022

von Rejeski, K. | Perez, A. | Iacoboni, G. | +17

10

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells

enthalten in: Neurology | 2022

von Karschnia, P. | Rejeski, K. | Winkelmann, M. | +10